A multicenter, open-label phase II trial of secondline apatinib plus irinotecan in patients with advanced gastric cancer

被引：0
|
作者：
Peng, Jianjun
Li, Yong
Xiao, Jianjun
Liu, Huaqiang
机构：
[1] Sun Yat Sen Univ, Affiliated Hosp 1, Guangzhou, Peoples R China
[2] Tradit Chinese Med Hosp Guangdong Prov, Guangzhou, Peoples R China
[3] Zhongshan City Peoples Hosp, Zhongshan, Peoples R China
[4] Cent Hosp Guangdong Prov Agr Reclamat, Zhanjiang, Guangdong, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 04期
关键词：
D O I：
10.1200/JCO.2022.40.4_suppl.287
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
287
引用
收藏
页数：3
相关论文
共 50 条
  • [41] Efficacy, safety and pharmacokinetics of apatinib plus etoposide versus apatinib alone for platinum-resistant recurrent ovarian cancer: protocol of a multicenter, open-label, randomized phase 2 trial
    Hou, Zhiguo
    Lan, Chunyan
    Huang, Xin
    Salcedo-Hernandez, Rosa A.
    EL-Tawab, Sally
    TRANSLATIONAL CANCER RESEARCH, 2023, 12 (10) : 2959 - 2967
  • [42] An open-label, phase II trial of cabozantinib for advanced adrenocortical carcinoma
    Campbell, M. T.
    Jimenez, C.
    Long, J. P.
    Varghese, J.
    Shah, A.
    Zhang, M.
    Tamsen, G.
    Habra, M. A.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S545 - S545
  • [43] A single-arm, open-label, prospective, multicenter study of apatinib combined with chemotherapy as second-line therapy in patients with advanced gastric cancer
    Feng, J.
    Shen, B.
    Xu, J.
    Wang, Q.
    Ling, G.
    Mao, Y.
    Cai, M.
    Yang, Y.
    Mei, J.
    Han, Z.
    Wu, Y.
    Shi, L.
    ANNALS OF ONCOLOGY, 2020, 31 : S913 - S913
  • [44] A multicenter, open-label, phase II trial of pemetrexed plus bevacizumab in elderly patients with previously untreated advanced or recurrent nonsquamous non-small cell lung cancer
    Yabuki, Yohei
    Hanibuchi, Masaki
    Takeuchi, Eiji
    Haku, Takashi
    Kanematsu, Takanori
    Nishimura, Naoki
    Toyoda, Yuko
    Mitsuhashi, Atsushi
    Otsuka, Kenji
    Sato, Seidai
    Goto, Hisatsugu
    Yoneda, Hiroto
    Ogino, Hirokazu
    Nokihara, Hiroshi
    Tsutomu, Shinohara
    Nishioka, Yasuhiko
    THORACIC CANCER, 2023, 14 (32) : 3232 - 3239
  • [45] A multicenter, open-label, phase II trial of pemetrexed plus bevacizumab in elderly patients with advanced or recurrent non-squamous non-small cell lung cancer
    Yabuki, Yohei
    Otsuka, Kenji
    Ogino, Hirokazu
    Takeuchi, Eiji
    Haku, Takashi
    Kanematsu, Takanori
    Nishimura, Naoki
    Toyoda, Yuko
    Hanibuchi, Masaki
    Mitsuhashi, Atsushi
    Tsukazaki, Yuki
    Ozaki, Ryohiko
    Yoneda, Hiroto
    Nokihara, Hiroshi
    Nisihioka, Yasuhiko
    RESPIROLOGY, 2023, 28 : 300 - 300
  • [46] Camrelizumab plus famitinib malate in patients with advanced renal cell cancer and unresectable urothelial carcinoma: A multicenter, open-label, single-arm, phase II trial.
    Qu, Yuan-Yuan
    Guo, Hongqian
    Luo, Hong
    Zou, Qing
    Xing, Ninazeng
    Sun, Zhongquan
    Zhang, Xuepei
    Xia, Shujie
    He, Chaohong
    Zhang, Hailiang
    Cai, Jinling
    Zhang, Xiao
    Wang, Quanren
    Ye, Dingwei
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [47] A multicenter, open-label, phase IIIB trial of erlotinib in patients with advanced non-small cell lung cancer
    Hainsworth, J
    Spigel, D
    O'Neill, V
    Klencke, B
    LUNG CANCER, 2005, 49 : S246 - S247
  • [48] Immunotherapy of Peritoneal Carcinomatosis with the Antibody Catumaxomab in Colon, Gastric, or Pancreatic Cancer: An Open-Label, Multicenter, Phase I/II Trial
    Stroehlein, Michael A.
    Lordick, Florian
    Ruettinger, Dominik
    Gruetzner, Klaus-Uwe
    Schemanski, Oliver C.
    Jaeger, Michael
    Lindhofer, Horst
    Hennig, Michael
    Jauch, Karl-Walter
    Peschel, Christian
    Heiss, Markus M.
    ONKOLOGIE, 2011, 34 (03): : 101 - 108
  • [49] Efficacy, tolerability, and safety of teverelix DP in patients with advanced prostate cancer: A multicenter, open-label, phase 2 trial
    Ulys, Albertas
    Jankevicus, Feliksas
    Jievaltas, Mindaugas
    Venckus, Raimundas
    Auskalnis, Stasys
    Kardelis, Zygimantas
    Barisiene, Marija
    Maclean, Carol M.
    van Os, Steve
    Larsen, Finn
    PROSTATE, 2024, 84 (06): : 584 - 598
  • [50] Anlotinib plus sintilimab in patients with recurrent advanced endometrial cancer: A prospective open-label, single-arm, phase II clinical trial
    Wei, W.
    Ban, X.
    Yang, F.
    Huang, Y.
    Li, J.
    Cheng, X.
    Zheng, M.
    Li, J.
    ANNALS OF ONCOLOGY, 2021, 32 : S762 - S762
12345